📊 INO Key Takeaways
Is INO a Good Investment? Thesis Analysis
Inovio Pharmaceuticals faces severe financial distress with collapsing revenues (-70% YoY), massive operating losses (-$86.8M), and negative free cash flow (-$88.9M) indicating the company is burning cash at an unsustainable rate. The company's debt-to-equity ratio of 2.60x combined with only $44.3M in cash against $62.8M in long-term debt creates significant solvency risk, with current operational performance unable to cover debt service obligations.
Why Buy INO? Key Strengths
- Net loss improved 20.8% YoY suggesting margin stabilization from peak losses
- Current ratio of 1.40x provides adequate short-term liquidity cushion
- Positive insider activity with 9 Form 4 filings in last 90 days
INO Investment Risks to Consider
- Revenue collapsed 70% YoY indicating loss of commercial traction or pipeline setback
- Negative free cash flow of -$88.9M with only $44.3M cash on hand indicates runway of ~6 months at current burn rate
- Debt-to-equity of 2.60x with negative interest coverage (-488.2x) creates imminent debt servicing crisis
- Operating margin of -132,871% reflects extreme unprofitability with minimal revenue relative to operating expenses
- Total liabilities exceed stockholders' equity by $26.1M indicating balance sheet impairment
Key Metrics to Watch
- Cash burn rate and months of cash runway remaining
- Quarterly revenue trends and pipeline advancement
- Debt refinancing ability and covenant compliance status
INO Financial Metrics
💡 AI Analyst Insight
INOVIO PHARMACEUTICALS, INC. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
INO Profitability Ratios
INO vs Healthcare Sector
How INOVIO PHARMACEUTICALS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INO Overvalued or Undervalued?
Based on fundamental analysis, INOVIO PHARMACEUTICALS, INC. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INO Balance Sheet & Liquidity
INO 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: INOVIO PHARMACEUTICALS, INC.'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-3.95 indicates the company is currently unprofitable.
INO Growth Metrics (YoY)
INO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$19.7M | $-0.87 |
| Q2 2025 | N/A | -$19.7M | $-0.61 |
| Q1 2025 | N/A | -$19.7M | $-0.51 |
| Q3 2024 | N/A | -$25.2M | $-0.89 |
| Q2 2024 | $100.8K | -$30.5M | $-1.19 |
| Q1 2024 | N/A | -$30.5M | $-1.31 |
| Q3 2023 | $388.4K | -$33.9M | $-0.13 |
| Q2 2023 | $226.0K | -$35.5M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INO Capital Allocation
INO SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for INOVIO PHARMACEUTICALS, INC. (CIK: 0001055726)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INO
What is the AI rating for INO?
INOVIO PHARMACEUTICALS, INC. (INO) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are INO's key strengths?
Claude: Net loss improved 20.8% YoY suggesting margin stabilization from peak losses. Current ratio of 1.40x provides adequate short-term liquidity cushion.
What are the risks of investing in INO?
Claude: Revenue collapsed 70% YoY indicating loss of commercial traction or pipeline setback. Negative free cash flow of -$88.9M with only $44.3M cash on hand indicates runway of ~6 months at current burn rate.
What is INO's revenue and growth?
INOVIO PHARMACEUTICALS, INC. reported revenue of $65.3K.
Does INO pay dividends?
INOVIO PHARMACEUTICALS, INC. does not currently pay dividends.
Where can I find INO SEC filings?
Official SEC filings for INOVIO PHARMACEUTICALS, INC. (CIK: 0001055726) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INO's EPS?
INOVIO PHARMACEUTICALS, INC. has a diluted EPS of $-1.81.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INO a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, INOVIO PHARMACEUTICALS, INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INO stock overvalued or undervalued?
Valuation metrics for INO: ROE of -352.5% (sector avg: 15%), net margin of -130,000.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INO stock in 2026?
Our dual AI analysis gives INOVIO PHARMACEUTICALS, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INO's free cash flow?
INOVIO PHARMACEUTICALS, INC.'s operating cash flow is $-88.6M, with capital expenditures of $285.7K. FCF margin is -136,074.5%.
How does INO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -130,000.0% (avg: 12%), ROE -352.5% (avg: 15%), current ratio 1.40 (avg: 2).